OLIVIA DORMAN: Open Payments
NPI 1679336846 · SALISBURY, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$621 in 23 payments from 13 companies in 2025. Trend: 2023 $0 · 2024 $2,145 · 2025 $621
Food & beverage: $621
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $101 |
| Regeneron Healthcare Solutions, Inc. | 3 | $85 |
| Verona Pharma, Inc. | 3 | $67 |
| GlaxoSmithKline, LLC. | 3 | $66 |
| Amgen Inc. | 2 | $50 |
| AstraZeneca Pharmaceuticals LP | 2 | $44 |
| Becton, Dickinson and Company | 1 | $41 |
| HARMONY BIOSCIENCES LLC | 1 | $40 |
| Genentech USA, Inc. | 1 | $28 |
| Vifor Pharma, Inc. | 1 | $27 |
Products named: DUPIXENT, GLASSIA, TEZSPIRE, Ohtuvayre, NUCALA, PleurX, WAKIX, Xolair.
Industry payments across MD — which companies pay providers there.
